Rhabdomyolysis developing secondary to atorvastatin therapy in a patient with liver cirrhosis

Internal Medicine

Volumn 52, Issue 7, 2013, Pages 823-825

  Eshraghian, Ahad ^a   Kamyab, Amir A'lam ^a  

^a SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Atorvastatin; Liver cirrhosis; Rhabdomyolysis

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; ATORVASTATIN; BICARBONATE; CALCIUM ION; CREATINE KINASE; LACTATE DEHYDROGENASE; PHOSPHORUS;

ACUTE KIDNEY FAILURE; AGED; ARTICLE; ASCITES; BLOOD GAS ANALYSIS; CASE REPORT; DRUG WITHDRAWAL; FEMALE; HUMAN; HYDRATION; HYPERKALEMIA; HYPERLIPIDEMIA; ISCHEMIC HEART DISEASE; LIMB PAIN; LIMB WEAKNESS; LIVER CIRRHOSIS; LIVER CLEARANCE; METABOLIC ACIDOSIS; MYALGIA; MYOGLOBINURIA; RHABDOMYOLYSIS; URINALYSIS;

AGED; ANTICHOLESTEREMIC AGENTS; FEMALE; HEPTANOIC ACIDS; HUMANS; LIVER CIRRHOSIS; PYRROLES; RHABDOMYOLYSIS;

EID: 84875881409     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.52.9272     Document Type: Article

References (18)

1. Van Linthout S, Riad A, Dhayat N, et al. Anti-inflammatory effects of atorvastatin improve left ventricular function in experimental diabetic cardiomyopathy. Diabetologia 50: 1977-1986, 2007.
2. Athyros VG, Tziomalos K, Karagiannis A, Mikhailidis DP. Atorvastatin: safety and tolerability. Expert Opin Drug Saf 9: 667-674, 2010.
3. Noordally SO, Sohawon S, Vanderhulst J, Duttmann R, Corazza F, Devriendt J. A fatal case of cutaneous adverse drug-induced toxic epidermal necrolysis associated with severe rhabdomyolysis. Ann Saudi Med 32: 309-311, 2012.
4. Ucar M, Mjörndal T, Dahlqvist R. HMG-CoA reductase inhibitors and myotoxicity. Drug Saf 22: 441-457, 2000.
5. Russo MW, Scobey M, Bonkovsky HL. Drug-induced liver injury associated with statins. Semin Liver Dis 29: 412-422, 2009.
6. Trebicka J, Hennenberg M, Odenthal M, et al. Atorvastatin attenuates hepatic fibrosis in rats after bile duct ligation via decreased turnover of hepatic stellate cells. J Hepatol 53: 702-712, 2010.
7. Foster T, Budoff MJ, Saab S, Ahmadi N, Gordon C, Guerci AD. Atorvastatin and antioxidants for the treatment of nonalcoholic fatty liver disease: the St Francis Heart Study randomized clinical trial. Am J Gastroenterol 106: 71-77, 2011.
8. Russo MW, Jacobson IM. How to use statins in patients with chronic liver disease. Cleve Clin J Med 71: 58-62, 2004.
9. Chalasani N, Gorski JC, Patel NH, Hall SD, Galinsky RE. Hepatic and intestinal cytochrome P450 3A activity in cirrhosis: effects of transjugular intrahepatic portosystemic shunts. Hepatology 34: 1103-1108, 2001.
10. Rosenson RS. Current overview of statin-induced myopathy. Am J Med 116: 408-416, 2004.
11. Graham DJ, Staffa JA, Shatin D, et al. Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA 292: 2585-2590, 2004.
12. Duell PB, Connor WE, Illingworth DR. Rhabdomyolysis after taking atorvastatin with gemfibrozil. Am J Cardiol 81: 368-369, 1998.
13. Magee CN, Medani SA, Leavey SF, Conlon PJ, Clarkson MR. Severe rhabdomyolysis as a consequence of the interaction of fusidic acid and atorvastatin. Am J Kidney Dis 56: e11-e15, 2010.
14. Mackay JW, Fenech ME, Myint KS. Acute rhabdomyolysis caused by combination therapy with atorvastatin and warfarin. Br J Hosp Med (Lond) 73: 106-107, 2012.
15. Strandell J, Bate A, Hägg S, Edwards IR. Rhabdomyolysis a result of azithromycin and statins: an unrecognized interaction. Br J Clin Pharmacol 68: 427-434, 2009.
16. Maltz HC, Balog DL, Cheigh JS. Rhabdomyolysis associated with concomitant use of atorvastatin and cyclosporine. Ann Pharmacother 33: 1176-1179, 1999.
17. Woodcroft KJ, Novak RF. Insulin differentially affects xenobioticenhanced, cytochrome P-450 (CYP) 2E1, CYP2B, CYP3A, and CYP4A expression in primary cultured rat hepatocytes. J Pharmacol Exp Ther 289: 1121-1127, 1999.
18. Minamiyama Y, Takemura S, Yamasaki K, et al. Continuous administration of organic nitrate decreases hepatic cytochrome P450. J Pharmacol Exp Ther 308: 729-735, 2004.